A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of HY05350 for Injection in Patients With MSLN-positive Advanced Solid Tumors
Latest Information Update: 01 Aug 2025
At a glance
- Drugs HY 05350 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Aug 2025 New trial record